Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2016 (2016), Article ID 3918292, 6 pages
Research Article

Immediate Adverse Reactions to Gadolinium-Based MR Contrast Media: A Retrospective Analysis on 10,608 Examinations

1Department of Diagnostic Imaging, Radiant and Metabolic Therapy, Istituto Nazionale Tumori “Fondazione G. Pascale” IRCCS, 80131 Naples, Italy
2Department of Anesthesia, Endoscopy and Cardiology, Istituto Nazionale Tumori “Fondazione G. Pascale” IRCCS, 80131 Naples, Italy
3UOC Anestesia e Terapia Intensiva, Presidio Ospedaliero “Pineta Grande” Castel Volturno, 81100 Caserta, Italy
4Department of Hepatobiliary Surgical Oncology, Istituto Nazionale Tumori “Fondazione G. Pascale” IRCCS, 80131 Naples, Italy

Received 24 February 2016; Revised 15 July 2016; Accepted 1 August 2016

Academic Editor: Marco Francone

Copyright © 2016 Vincenza Granata et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Background and Purpose. Contrast media (CM) for magnetic resonance imaging (MRI) may determine the development of acute adverse reactions. Objective was to retrospectively assess the frequency and severity of adverse reactions associated with gadolinium-based contrast agents (GBCAs) injection in patients who underwent MRI. Material and Methods. At our center 10608 MRI examinations with CM were performed using five different GBCAs: Gd-BOPTA (MultiHance), Gd-DTPA (Magnevist), Gd-EOBDTPA (Primovist), Gd-DOTA (Dotarem), and Gd-BTDO3A (Gadovist). Results. 32 acute adverse reactions occurred, accounting for 0.3% of all administration. Twelve reactions were associated with Gd-DOTA injection (0.11%), 9 with Gd-BOPTA injection (0.08%), 6 with Gd-BTDO3A (0.056%), 3 with Gd-EOB-DTPA (0.028%), and 2 with Gd-DTPA (0.018%). Twenty-four reactions (75.0%) were mild, four (12.5%) moderate, and four (12.5%) severe. The most severe reactions were seen associated with use of Gd-BOPTA, with 3 severe reactions in 32 total reactions. Conclusion. Acute adverse reactions are generally rare with the overall adverse reaction rate of 0.3%. The most common adverse reactions were not severe, consisting in skin rash and hives.